Evidence map›Paper›PMID 41750765›Full record

ArticleDiagnostics (Basel, Switzerland)2026

Cervical Adenocarcinoma In Situ in Young Nulliparous Patient with Persistent ASC-US and Multiple-Type HPV Infections Without HPV 16 and 18 Types-Case Report.

Nikola Milic, Marija Varnicic Lojanica, Stefan Ivanovic, Milica Ivanovic, Katarina Ivanovic, Nikola Jovic

Abstract readCase Reports
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nikola MilicUžice General Hospital, 31000 Užice, Serbia.ORCID 0009-0001-8143-5828
Marija Varnicic LojanicaUžice General Hospital, 31000 Užice, Serbia.ORCID 0009-0006-5128-9045
Stefan IvanovicObstetrics and Gynecology Clinic "Narodni Front", 11000 Belgrade, Serbia.ORCID 0009-0006-3269-3069
Milica IvanovicObstetrics and Gynecology Clinic "Narodni Front", 11000 Belgrade, Serbia.ORCID 0009-0000-3144-0779
Katarina IvanovicClinic for Gynecology and Obstetrics, University Clinical Center of Serbia, 11000 Belgrade, Serbia.ORCID 0000-0001-9176-9736
Nikola JovicDepartment of Gynecology and Obstetrics, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.ORCID 0000-0002-3269-1577

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The most severe premalignant lesion of glandular epithelium of the cervix is adenocarcinoma in situ (AIS). In most cases it is associated with persistent human papillomavirus (HPV) infection and most often occurs in women in the fourth decade of life. In most high-income countries, primary screening has shifted to HPV testing, while cytology is used for patient triage. Even with current robust screening protocols, their sensitivity for glandular lesions remains limited. Diagnosis of AIS obtained by biopsy, brushing or curettage is confirmed by excisional methods and pathohistological verification. Therapy depends on the patient's lifestyle and reproductive age. In our case, we present a nulliparous patient with persistent ASC-US, multiple-type HPV infection without HPV 16 and 18 types, and AIS which was diagnosed after conization, follow-up and two biopsies with curettage of cervical canal. Our case report highlights limitations in detection of glandular lesions and need for caution in patients with persistent and seemingly low-grade cytological abnormalities, notably in young patients with high-risk HPV types.

Indexed as

adenocarcinoma in situASC-UScervix uterihuman papillomavirus

Identifiers

PMID41750765
PMCPMC12938978

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.